6571 POSTER Impact of Prior Somatostatin Analog (SSA) Use on PFS in the Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Patients With Advanced Neuroendocrine Tumours (RADIANT-2)

• DOI: 10.1016/s0959-8049(11)71882-2
• Publication Date: 2011-09-26T05:49:33Z
• Authors: M. Pavel; N. Singh; V. Passos; K. Oberg
• Keywords: Everolimus